Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cyclin-dependent kinase 5 | Starlite/ChEMBL | References |
Homo sapiens | cyclin-dependent kinase 3 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | mitogen-activated protein kinase 5 | cyclin-dependent kinase 5 | 260 aa | 307 aa | 28.3 % |
Trypanosoma brucei | mitogen-activated protein kinase 5 | cyclin-dependent kinase 3 | 305 aa | 303 aa | 32.0 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Chlamydia trachomatis | sulfite reductase | 0.0465 | 0.5568 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0753 | 1 | 0.5 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0288 | 0.2846 | 0.2833 |
Leishmania major | cytochrome P450 reductase, putative | 0.0667 | 0.8683 | 0.8681 |
Loa Loa (eye worm) | hypothetical protein | 0.0753 | 1 | 1 |
Plasmodium falciparum | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0288 | 0.2846 | 0.2833 |
Treponema pallidum | flavodoxin | 0.0288 | 0.2846 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0379 | 0.4251 | 0.4241 |
Schistosoma mansoni | diflavin oxidoreductase | 0.0374 | 0.4163 | 0.4153 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0753 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0753 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0288 | 0.2846 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0288 | 0.2846 | 1 |
Echinococcus multilocularis | methionine synthase reductase | 0.0465 | 0.5568 | 0.556 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0288 | 0.2846 | 0.2833 |
Leishmania major | p450 reductase, putative | 0.0753 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0288 | 0.2846 | 0.2833 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0753 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0753 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0288 | 0.2846 | 1 |
Echinococcus granulosus | methionine synthase reductase | 0.0465 | 0.5568 | 0.556 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0753 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0288 | 0.2846 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0753 | 1 | 1 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0667 | 0.8683 | 0.8681 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0288 | 0.2846 | 0.2833 |
Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0104 | 0.0017 | 0.0017 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0753 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0288 | 0.2846 | 1 |
Brugia malayi | flavodoxin family protein | 0.0288 | 0.2846 | 0.2833 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0753 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0465 | 0.5568 | 0.556 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0753 | 1 | 1 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0288 | 0.2846 | 0.2833 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0667 | 0.8683 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0374 | 0.4163 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0753 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0753 | 1 | 1 |
Loa Loa (eye worm) | CMGC/CDK/CDK5 protein kinase | 0.0104 | 0.0017 | 0.0017 |
Trypanosoma cruzi | p450 reductase, putative | 0.0753 | 1 | 1 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0667 | 0.8683 | 0.8681 |
Giardia lamblia | Hypothetical protein | 0.0667 | 0.8683 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0465 | 0.5568 | 0.5568 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0753 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0753 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0753 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0753 | 1 | 1 |
Plasmodium falciparum | NADPH--cytochrome P450 reductase, putative | 0.0288 | 0.2846 | 0.2833 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0753 | 1 | 1 |
Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0104 | 0.0017 | 0.0017 |
Trypanosoma brucei | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0288 | 0.2846 | 0.2833 |
Brugia malayi | FAD binding domain containing protein | 0.0465 | 0.5568 | 0.556 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0288 | 0.2846 | 0.2833 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0753 | 1 | 1 |
Plasmodium vivax | hypothetical protein, conserved | 0.0288 | 0.2846 | 0.2833 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0753 | 1 | 1 |
Loa Loa (eye worm) | flavodoxin family protein | 0.0288 | 0.2846 | 0.2846 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0288 | 0.2846 | 0.2833 |
Trypanosoma cruzi | NADPH--cytochrome P450 reductase, putative | 0.0288 | 0.2846 | 0.2833 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0374 | 0.4163 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 2.5 uM | Inhibition of Cyclin-dependent kinase 1 (CDK1) | ChEMBL. | 11063606 |
IC50 (binding) | = 2.5 uM | Inhibition of Cyclin-dependent kinase 1 (CDK1) | ChEMBL. | 11063606 |
IC50 (binding) | = 8 uM | Inhibitory activity against Cyclin-dependent kinase 5 | ChEMBL. | 11063606 |
IC50 (binding) | = 8 uM | Inhibitory activity against Cyclin-dependent kinase 5 | ChEMBL. | 11063606 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.